These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22938159)

  • 41. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation.
    Kobayashi T; Maruya E; Niwa M; Saji H; Kohara S; Katayama A; Takeda A; Watarai Y; Uchida K
    Hum Immunol; 2011 Jan; 72(1):11-7. PubMed ID: 20974206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation.
    Irving CA; Carter V; Gennery AR; Parry G; Griselli M; Hasan A; Kirk CR
    J Heart Lung Transplant; 2015 Oct; 34(10):1310-7. PubMed ID: 26123951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy.
    Chung BH; Choi BS; Oh EJ; Park CW; Kim JI; Moon IS; Kim YS; Yang CW
    Transpl Int; 2014 Jan; 27(1):49-59. PubMed ID: 24118413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients.
    Wu P; Everly MJ; Jin J; Mao Y; Chen J
    Clin Transpl; 2011; ():365-8. PubMed ID: 22755432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
    Mujtaba MA; Goggins W; Lobashevsky A; Sharfuddin AA; Yaqub MS; Mishler DP; Brahmi Z; Higgins N; Milgrom MM; Diez A; Taber T
    Clin Transplant; 2011; 25(1):E96-102. PubMed ID: 20977497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
    Kimball PM; King A
    Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.
    Bosch A; Llorente S; Diaz JA; Salgado G; López M; Boix F; López-Hernández R; González-Soriano MJ; Campillo JA; Moya-Quiles MR; Perez-Lopez N; Minguela A; Jimeno L; Alvarez-López MR; Muro M
    Hum Immunol; 2012 May; 73(5):522-5. PubMed ID: 22425738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring of circulating antibodies in a renal transplantation population: preliminary results.
    Rodríguez Ferrero ML; Arroyo D; Panizo N; Vicario JL; Balas A; Anaya F
    Transplant Proc; 2012 Nov; 44(9):2548-50. PubMed ID: 23146450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
    Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
    Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-human leukocyte antigen immunization after early allograft nephrectomy.
    Del Bello A; Congy N; Sallusto F; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Cointault O; Lavayssière L; Nogier MB; Game X; Blancher A; Rostaing L; Kamar N
    Transplantation; 2012 May; 93(9):936-41. PubMed ID: 22361471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients.
    Mohamed MA; Muth B; Vidyasagar V; Foley D; Fernandez L; Hofmann RM; Mezrich J; Pirsch J; Odorico J; d'Alessandro T; Bellingham J; Torrealba J; Kaufman D; Djamali A
    Clin Transpl; 2011; ():389-94. PubMed ID: 22755436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
    Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
    Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearance.
    Wu P; Everly MJ; Rebellato LM; Haisch CE; Briley KP; Bolin P; Kendrick WT; Kendrick SA; Morgan C; Harland RC; Terasaki PI
    Transplantation; 2013 Nov; 96(10):919-25. PubMed ID: 23912173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
    Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
    Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.